Recruiting
Phase 2

Brenipatide with Antidepressant

Sponsor:

Eli Lilly and Company

Code:

NCT07928245

Conditions

Major Depressive Disorder

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Brenipatide

Placebo

Study Details

Brief summary:

This study evaluates the safety and efficacy of brenipatide (LY3537031) as an add on therapy in participants with major depression who still have symptoms while taking a stable dose of standard of care anti-depressant medicine.

The study will last approximately 5 months.

Conditions

Major Depressive Disorder

Study ID

NCT07928245

Start date

Nov 10, 2026

Status verified date

Nov, 2026

Completion date

Jul, 2028

Anticipated

Primary completion date

May, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Have a diagnosis of Major Depressive Disorder (MDD) and are in a current major depressive episode, without psychotic features
  • Are on a stable antidepressant monotherapy regimen for the current major depressive episode
  • Are a partial responder to the current antidepressant monotherapy regimen
  • Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as:

  • self-inject study intervention
  • store and use the provided blinded study intervention, as directed
  • maintain electronic and paper study diaries, as applicable, and
  • complete the required questionnaires

Exclusion Criteria:

  • Have a lifetime history or current diagnosis of the following:

  • schizophrenia or other psychotic disorder
  • bipolar disorder
  • borderline personality disorder
  • other personality disorders that would interfere with compliance with the study protocol
  • neurocognitive disorders or intellectual disability, or
  • any eating disorder
  • Have type 1 diabetes mellitus, or a history of

  • ketoacidosis, or
  • hyperosmolar state or coma
  • Have had a history of any substance or alcohol use disorder of any severity within 180 days before Visit 1
  • Are actively suicidal or deemed a significant risk for suicide
  • Have participated in a clinical study and received active treatment, or unknown if they received active treatment, within 90 days or 5 half-lives (whichever is longer) before Visit 1

Study Design

Enrollment

330 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Brenipatide

Brenipatide administered subcutaneously (SC) + standard of care (SoC) anti-depressant

placebo comparator: Placebo

Placebo administered SC + SoC anti-depressant

Interventions

Brenipatide

Administered SC

Placebo

Administered SC

Primary outcome measure

  • Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS-9) Score [ Time Frame: Baseline, Week 10 ]

Central Contacts and Locations

Central contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Locations

Inland Psychiatric Medical Group

Recruiting

Chino, California, United States, 91710

Contacts

Principal Investigator:

Nandita Puchakayala

Denali Health - Plant City, FL

Recruiting

Plant City, Florida, United States, 33563

Contacts

Principal Investigator:

Walid Aziz

More Information

Sponsor

Eli Lilly and Company

Last update posted

Nov 20, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.